Acumen Pharmaceuticals (ABOS) vs Coherus Oncology (CHRS)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Acumen Pharmaceuticals (ABOS) has outperformed Coherus Oncology (CHRS) over the past year, gaining 11.7% versus a loss of 40.9%. Over five years, ABOS leads with a -84.5% price change compared with -94.1% for CHRS. Coherus Oncology is the larger company by market cap ($156.0 million vs $148.6 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ABOS | CHRS |
|---|---|---|
| Share price | $2.06 | $1.01 |
| Market cap | $148.61M | $156.03M |
| 1-day change | -2.14% | -0.01% |
| YTD return | -0.47% | -28.87% |
| 1-year return | +11.70% | -40.94% |
| 5-year return | -84.50% | -94.06% |
| EPS (TTM) | $-1.64 | $-1.25 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $3.60 | $2.62 |
| 52-week low | $1.50 | $1.00 |
| Distance from 52-week high | -42.92% | -61.40% |
| Analyst consensus | strong_buy | none |
| Avg. price target upside | +269.83% | +667.40% |
| Average volume | 435.44K | 1.15M |
| Shares outstanding | 72.32M | 154.50M |
| Employees | 60 | 144 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- ABOS has outperformed CHRS by 52.6 percentage points over the past year.
About Acumen Pharmaceuticals
ABOS stock →Acumen Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops targeted therapies for the treatment of Alzheimer's disease. It focuses on advancing a targeted immunotherapy drug candidate, sabirnetug (ACU193), which is in its Phase 2 ALTITUDE-AD clinical trial to target toxic soluble amyloid beta oligomers.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 60 employees
About Coherus Oncology
CHRS stock →Coherus Oncology, Inc., a biopharmaceutical company, researches, develops, and commercializes immunotherapies to treat cancer in the United States. The company develops UDENYCA, a biosimilar to Neulasta, a long-acting granulocyte-colony stimulating factor; LOQTORZI, a novel next-generation programmed death receptor-1 inhibitor; and Casdozokitug, an investigational recombinant human immunoglobulin isotype (IgG1) monoclonal antibody targeting interleukin IL-27.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 144 employees
ABOS vs CHRS FAQ
Which is bigger, Acumen Pharmaceuticals or Coherus Oncology?
Coherus Oncology (CHRS) is larger, with a market capitalization of $156.03M compared with $148.61M for Acumen Pharmaceuticals (ABOS).
Which stock has performed better over the past year, ABOS or CHRS?
ABOS returned +11.70% over the past 12 months, compared with -40.94% for CHRS (price return, excluding dividends). Past performance does not predict future results.
Are Acumen Pharmaceuticals and Coherus Oncology in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.